In conclusion, this large randomized comparison shows a potential favourable effect of a dual PPAR-α/γ agonist on NITs for liver steatosis and fibrosis in a high-risk population for NAFLD of overweight patients with T2DM. This evidence concerns the gene PPARA and type 2 diabetes mellitus.